企業プロフィール
Praxis Precision Medicines 株価・ニュース・カタリスト
- ティッカー:
- PRAX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
375.94 USD (+3.12%)
終値
最終更新: 2026年8月21日
7.19B USD
時価総額
株価変動の要因
As of Aug 21, 2026, PRAX closed up 3.12% at $375.94. No new same-company headline was identified in the current news window.
企業概要
Precision Neuroscience
Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies.
Ulixacaltamide
Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential tremor.
Relutrigine
Relutrigine is under Priority Review for SCN2A- and SCN8A-related developmental and epileptic encephalopathies.
Vormatrigine
Vormatrigine is an oral precision medicine being evaluated in the POWER1 study for focal-onset seizures.
Elsunersen
Elsunersen is an antisense oligonucleotide targeting the underlying biology of SCN2A-related developmental and epileptic encephalopathy.
今後のカタリスト
- Topline POWER1 results for vormatrigine in the second quarter of 2026.
- PDUFA target date for relutrigine on September 27, 2026.
- Topline EMERALD results for relutrigine in broad developmental and epileptic encephalopathies in the fourth quarter of 2026.
- PDUFA target date for ulixacaltamide on January 29, 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。